We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.23 | 0.77% | 30.25 | 30.15 | 30.26 | 30.28 | 30.07 | 30.10 | 2,908,982 | 22:20:00 |
From Apr 2019 to Apr 2024
By Dave Sebastian
Genentech Inc. received accelerated approval for its Rozlytrek treatment for cancer with the NTRK genetic defect, the U.S. Food and Drug Administration said Thursday.
The treatment has gone through four clinical trials studying adults with tumors caused by the genetic defect, the FDA said. The trials demonstrated the ability to shrink tumors in 57% of patients and to eliminate them in 7.4% of patients.
FDA also approved Rozlytrek for its treatment of adults with non-small cell lung cancer with ROS1-positive tumors and has spread to other parts of the body.
"We're seeing continued advances in the use of biomarkers to guide drug development and the more targeted delivery of medicine," FDA Acting Commissioner Ned Sharpless said in a statement.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
August 15, 2019 16:21 ET (20:21 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
